Mayne Pharma opens expanded adelaide facility after $18m investment

Mayne Pharma has officially opened its expanded manufacturing facility in Salisbury, South Australia, following an approximately $18 million investment over the past two years. This modernisation includes a new high-speed encapsulation suite and automation upgrades, enhancing production efficiency and quality for solid oral and topical dosage forms. The facility is GMP, FDA, and TGA accredited, situated on a 12-hectare site.

The modernisation program received a $4.8 million federal government modern manufacturing initiative (MMI) grant, with full funding obtained by June 2025. The completed upgrade significantly boosts Mayne Pharma’s manufacturing capacity and capabilities, including serialisation, supporting new product launches and exports.

For FY25, Mayne Pharma’s international segment reported a 7% increase in revenues to $75.6 million. Gross profit grew 1% to $21.5 million, with direct contribution reaching $7.4 million. The event was officiated by the hon Joe Szakacs MP and the hon Zoe Bettison MP.